drugset / Trial / NCT00307632

An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of Norelgestromine and Ethinyl Estradiol

NCT00307632

Phase 4 Completed 580 enrolled Janssen-Cilag Farmaceutica Ltda.
Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the contraceptive efficacy, safety, cycle control, compliance, and subject satisfaction of the transdermal contraceptive system, norelgestromine and ethinyl estradiol (NLGM / EE).

Timeline

Start
2003-02
Primary completion
2004-12
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Norelgestromine Unknown 150 ug Other
Subject ethinyl estradiol Small molecule 20 ug Other

Indications

No indication recorded.